<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Hypertension</journal-id><journal-id journal-id-type="iso-abbrev">Hypertension</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Hypertension (Dallas, Tex. : 1979)</journal-title></journal-title-group><issn pub-type="ppub">0194-911X</issn><issn pub-type="epub">1524-4563</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10023512</article-id><article-id pub-id-type="pmcid-ver">PMC10023512.1</article-id><article-id pub-id-type="pmcaid">10023512</article-id><article-id pub-id-type="pmcaiid">10023512</article-id><article-id pub-id-type="manuscript-id">NIHMS1862155</article-id><article-id pub-id-type="pmid">36756872</article-id><article-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.122.17947</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1862155</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1862155</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Established and Emerging Cancer Therapies and Cardiovascular System: focus on hypertension &#8211; mechanisms and mitigation</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Butel-Simoes</surname><given-names initials="LE">Lloyd E</given-names></name><xref rid="FN1" ref-type="author-notes">*</xref><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Haw</surname><given-names initials="TJ">Tatt Jhong</given-names></name><xref rid="FN1" ref-type="author-notes">*</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Williams</surname><given-names initials="T">Trent</given-names></name><xref rid="FN1" ref-type="author-notes">*</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sritharan</surname><given-names initials="S">Shanathan</given-names></name><xref rid="A5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gadre</surname><given-names initials="P">Payal</given-names></name><xref rid="A5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Herrmann</surname><given-names initials="SM">Sandra M</given-names></name><xref rid="A6" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Herrmann</surname><given-names initials="J">Joerg</given-names></name><xref rid="A7" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ngo</surname><given-names initials="DTM">Doan TM</given-names></name><xref rid="FN2" ref-type="author-notes">#</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sverdlov</surname><given-names initials="AL">Aaron L</given-names></name><xref rid="FN2" ref-type="author-notes">#</xref><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref><xref rid="A4" ref-type="aff">4</xref></contrib></contrib-group><aff id="A1"><label>1</label>Cardiovascular Department, John Hunter Hospital, Newcastle, NSW, Australia</aff><aff id="A2"><label>2</label>College of Health and Medicine, University of Newcastle, NSW Australia</aff><aff id="A3"><label>3</label>Newcastle Centre of Excellence in Cardio-Oncology, NSW, Australia</aff><aff id="A4"><label>4</label>Hunter Medical Research Institute, New Lambton Heights, NSW Australia</aff><aff id="A5"><label>5</label>Department of Medicine, Hunter New England Local Health District, NSW, Australia</aff><aff id="A6"><label>6</label>Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota</aff><aff id="A7"><label>7</label>Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55902, USA</aff><author-notes><fn fn-type="other" id="FN1"><label>*</label><p id="P1">Drs LE Butel-Simoes, TJ Haw and T Williams are joint first authors on this manuscript</p></fn><fn fn-type="other" id="FN2"><label>#</label><p id="P2">Drs DTM Ngo and AL Sverdlov are co-senior and co-corresponding authors on this manuscript</p></fn><corresp id="CR1"><bold>Corresponding authors: Prof Doan TM Ngo</bold>, B.Pharm, PhD, FESC, FCSANZ, School of Biomedical Science and Pharmacy, College of Health, Medicine and Wellbeing, The University of Newcastle, NSW, Australia, T: +61 2 4033 9386, M: +61 (0) 413 822334, <email>doan.ngo@newcastle.edu.au</email>; <bold>Prof Aaron L Sverdlov</bold>, MBBS, PhD, FRACP, FCSANZ, FESC, FACC, School of Medicine and Public Health, College of Health, Medicine and Wellbeing, The University of Newcastle, NSW, Australia, T: +61 2 4042 0725, M: +61 (0) 478 113374, <email>aaron.sverdlov@newcastle.edu.au</email></corresp></author-notes><pub-date pub-type="ppub"><month>4</month><year>2023</year></pub-date><pub-date pub-type="epub"><day>09</day><month>2</month><year>2023</year></pub-date><volume>80</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">431553</issue-id><fpage>685</fpage><lpage>710</lpage><pub-history><event event-type="nihms-submitted"><date><day>06</day><month>01</month><year>2023</year></date></event><event event-type="pmc-release"><date><day>01</day><month>04</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>01</day><month>04</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-13 22:25:15.230"><day>13</day><month>09</month><year>2024</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1862155.pdf"/><abstract id="ABS1"><p id="P3">Cardiovascular disease and cancer are two of the leading causes of death worldwide. While improvements in outcomes have been noted for both disease entities, the success of cancer therapies has come at the cost of at times very impactful adverse events such as cardiovascular events. Hypertension has been noted as both, a side effect as well as a risk factor for the cardiotoxicity of cancer therapies. Some of these dynamics are in keeping with the role of hypertension as a cardiovascular risk factor not only for heart failure, but also for the development of coronary and cerebrovascular disease, and kidney disease and its association with a higher morbidity and mortality overall. Other aspects, such as the molecular mechanisms underlying the amplification of acute and long-term cardiotoxicity risk of anthracyclines and increase in blood pressure with various cancer therapeutics remain to be elucidated. In this review, we cover the latest clinical data regarding the risk of hypertension across a spectrum of novel anti-cancer therapies as well as the underlying known or postulated pathophysiological mechanisms. Further, we review the acute and long-term implications for the amplification of the development cardiotoxicity with drugs not commonly associated with hypertension such as anthracyclines. An outline of management strategies, including pharmacological and lifestyle interventions as well as models of care aimed to facilitate early detection and more timely management of hypertension in cancer patients and survivors concludes this review, which overall aims to improve both cardiovascular and cancer-specific outcomes.</p></abstract><kwd-group><kwd>Cardio-oncology</kwd><kwd>Hypertension</kwd><kwd>Cancer therapy</kwd><kwd>Epidemiology</kwd><kwd>Etiology</kwd><kwd>Mechanisms</kwd><kwd>Management</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>